Addex Therapeutics Ltd. filed a 6-K to provide unaudited interim condensed consolidated financial statements and management's discussion and analysis of financial condition and results of operations for the period ending December 31, 2025. The filing includes a company press release. Addex Therapeutics Ltd. is a clinical-stage biopharmaceutical company.